Literature DB >> 16822504

Glucosamine sulfate inhibits leukocyte adhesion in response to cytokine stimulation of retinal pigment epithelial cells in vitro.

Jiann-Torng Chen1, Po-Liang Chen, Yun-Hsiang Chang, Ming-Wei Chien, Yi-Hao Chen, Da-Wen Lu.   

Abstract

Glucosamine is an amine-containing sugar that exhibits immunosuppressive effects in vitro and in vivo, although its mechanism of action is unknown. We investigated whether glucosamine sulfate (GS) modulates the proinflammatory cytokine interleukin (IL)-1beta-induced expression and production of intercellular adhesion molecule (ICAM)-1, the mechanism responsible for this effect, and whether GS inhibits leukocyte adhesion to the monolayer of retinal pigment epithelial (RPE) cells stimulated with various cytokines. We used flow cytometry and an ARPE-19 cell model to determine the effect of GS on the production of ICAM-1 in response to IL-1beta, IL-6, tumor necrosis factor (TNF)-alpha plus IL-1beta, TNF-alpha plus IL-6, and TNF-alpha plus interferon (IFN)-gamma. We also used semiquantitative RT-PCR to determine the effect of GS on IL-1beta-induced expression of the ICAM-1 gene, and immunocytochemistry and western blotting to measure the effect of GS on the activation and nuclear translocation of the nuclear factor NF-kappaB and the degradation of cytoplasmic IkappaB. The functionality of GS-modulated ICAM-1 on leukocyte adhesion was demonstrated in an RPE cell-neutrophil adherence assay. IL-1beta increased the expression of ICAM-1 at the mRNA and protein levels in ARPE-19 cells. GS downregulated the production of ICAM-1 induced by IL-1beta, IL-6, TNF-alpha, and IFN-gamma at the protein level in a dose-dependent manner. GS also inhibited the nuclear translocation of NF-kappaB subunit p65 and partially prevented the degradation of cytoplasmic IkappaB in IL-1beta-stimulated ARPE-19 cells. GS significantly decreased the number of neutrophils adhering to the RPE monolayer in response to cytokines IL-1beta, IL-6, TNF-alpha, and IFN-gamma. GS inhibits the expression of the ICAM-1 gene in ARPE-19 cells stimulated with IL-1beta by blocking NF-kappaB subunit p65 translocation and by partially preventing IkappaB degradation. GS also decreases leukocyte adhesion to the monolayer of ARPE-19 cells stimulated with various cytokines by decreasing ICAM-1 production. Our study demonstrates a potentially important property of GS in reducing ICAM-1-mediated inflammatory mechanisms in the eye.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822504     DOI: 10.1016/j.exer.2006.05.010

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  5 in total

1.  Acute O-GlcNAcylation prevents inflammation-induced vascular dysfunction.

Authors:  Rob H P Hilgers; Dongqi Xing; Kaizheng Gong; Yiu-Fai Chen; John C Chatham; Suzanne Oparil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-07-09       Impact factor: 4.733

2.  Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury.

Authors:  Dongqi Xing; Wenguang Feng; Laszlo G Nöt; Andrew P Miller; Yun Zhang; Yiu-Fai Chen; Erum Majid-Hassan; John C Chatham; Suzanne Oparil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-09       Impact factor: 4.733

3.  Glucosamine inhibits epidermal growth factor-induced proliferation and cell-cycle progression in retinal pigment epithelial cells.

Authors:  Chang-Min Liang; Ming-Cheng Tai; Yun-Hsiang Chang; Yi-Hao Chen; Ching-Long Chen; Ming-Wei Chien; Jiann-Torng Chen
Journal:  Mol Vis       Date:  2010-12-03       Impact factor: 2.367

4.  Proliferative vitreoretinopathy: current and emerging treatments.

Authors:  Ama Sadaka; Gian Paolo Giuliari
Journal:  Clin Ophthalmol       Date:  2012-08-14

5.  Silibinin inhibits ICAM-1 expression via regulation of N-linked and O-linked glycosylation in ARPE-19 cells.

Authors:  Yi-Hao Chen; Ching-Long Chen; Chang-Min Liang; Jy-Been Liang; Ming-Cheng Tai; Yun-Hsiang Chang; Da-Wen Lu; Jiann-Torng Chen
Journal:  Biomed Res Int       Date:  2014-06-17       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.